Related Experiment Video
Updated: Sep 16, 2026

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
Deciphering the Combined Effects of Hydroxysafflor Yellow A and Calycosin Through Coupled PK-PD Modeling
Yanxuan Hu1, Xixi Zhao2, Weifeng Jin3
1The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Abstract:
To quantitatively characterize the pharmacokinetic and pharmacodynamic interactions between Hydroxysafflor Yellow A (HSYA) and Calycosin (CA) in cerebral ischemia-reperfusion injury (CIRI), a factorial experimental design was combined with a hierarchical coupled PK-PD modeling framework. The coupled PK model adequately described the concentration-time profiles of HSYA and CA under co-administration, with R2 values of 0.83 and 0.86, respectively, while the PK-PD model showed good fitting performance for Caspase-3 and HIF-1α, with all R2 values exceeding 0.97. Structural identifiability analysis showed that the newly introduced PK and PD coupling parameters were globally identifiable, and their Bootstrap 95% confidence intervals excluded zero. After Holm-Bonferroni correction, AUC0-t, AUC0-∞ and CL differed significantly between single and combined administration, whereas MRT did not. The model-derived relative contribution weights of HSYA and CA were quantified for both Caspase-3 and HIF-1α, with uncertainty assessed using Bootstrap 95% confidence intervals. Overall, the proposed coupled PK-PD framework provides a quantitative approach for characterizing component interactions and relative pharmacodynamic contributions in multi-component systems.
Related Concept Videos
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Pharmacodynamic Models: Overview
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Physiological Pharmacokinetic Models: Assumption with Protein Binding